University of Chicago

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Chicago sits in the top decile of US sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count).

796 total trials 158 currently recruiting 451 completed early-phase tilt top decile by trial count

University of Chicago: 796 sponsored US clinical trials, 158 recruiting.

University of Chicago sponsors 796 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 451 completed. 67 of these trials are in Phase 3-4 (later-stage) and 293 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 11 trials.

Top-decile sponsor footprint

University of Chicago ranks in the top decile of sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 40/100

451 of 562 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

796 total, page 15 of 16

COMPLETED Phase 2

Comparing the Effectiveness of Three Types of Therapy for the Treatment of Anorexia Nervosa in Adolescents

NCT00183586

TERMINATED Phase 4

Correlation of Nasal Volume, Cross-Sectional Area With Nasalance Scores Measured by Acoustic Rhinometry and Nasometry

NCT00147940

COMPLETED Phase 4

Changes in Nasal Patency With Changes in Posture, Temperature, Humidity and Nasal Patency Seen by Acoustic Rhinometry

NCT00147888

COMPLETED Phase 2

A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck

NCT00203905

COMPLETED

Prostate Cancer Utilities and Cost-Effectiveness Analysis

NCT00203918

TERMINATED Phase 1

The Significance of Glucose Intolerance in the Pathogenesis of Idiopathic Axonal Polyneuropathy

NCT00228345

COMPLETED NA

Chest Wall Oscillation for Asthma and COPD Exacerbations Trial (COAT)

NCT00181285

TERMINATED

C.A.T.C.H.-I.T.Competent Adulthood Transition With Cognitive, Humanistic and Interpersonal Teaching

NCT00152529

TERMINATED Phase 2

Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma

NCT00203866

TERMINATED Phase 4

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

NCT00203996

TERMINATED Phase 2

Sildenafil and Pulmonary Artery Pressure

NCT00145938

COMPLETED NA

The Effectiveness of Improving Compliance With Diabetic Preventative Services and Modifying Vascular Risk

NCT00204282

TERMINATED Phase 2

Nesiritide in Chronic Heart Failure

NCT00145873

COMPLETED Phase 2

A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder

NCT00078754

TERMINATED Phase 1

Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

NCT00943293

COMPLETED Phase 1

Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma

NCT00203892

COMPLETED Phase 2

A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer

NCT01693718

COMPLETED

Organ Preservation in the Multispeciality Therapy of Stage II-IV Locally Advanced Head and Neck Cancer

NCT01187472

TERMINATED NA

Physical Therapy for Systemic Lupus Erythematosus (SLE)

NCT00152555

COMPLETED Phase 2

Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine

NCT00053222

TERMINATED Phase 1

rhPTH Therapy for Low Turnover Bone Fragility

NCT00145886

COMPLETED Phase 2

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

NCT01185171

COMPLETED Phase 4

Tumor Gene Expression in Women With Ovarian Cancer

NCT00817479

COMPLETED NA

Extended Work Schedules, Sleep Loss and Health

NCT00989534

COMPLETED

Transfer to Another Health Care Facility Following Critical Illness

NCT00484445

COMPLETED Phase 2

High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

NCT00774046

COMPLETED Phase 3

Drug Treatment for Pathologic Gambling Disorder

NCT00053677

TERMINATED Phase 2

Assessing CPR Quality During In-Hospital Cardiac Arrest

NCT00228293

TERMINATED

Measurement of Jugular Venous Pulse in Critically Ill Patients.

NCT00303355

COMPLETED

International Adoption and Stress Response Study

NCT00203944

COMPLETED Phase 2

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

NCT01185158

COMPLETED Phase 4

Comparison of Sirolimus and Azathioprine in Lung Transplantation

NCT00321906

TERMINATED

Do Patients With Colorectal Cancer Understand That Their Family is at Risk?

NCT00145860

COMPLETED Phase 2

Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma

NCT00203879

COMPLETED Phase 2

A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With IED

NCT00127400

COMPLETED

Childhood Obesity: Variations in Management

NCT00160914

COMPLETED Phase 2

Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

NCT00025389

COMPLETED Phase 2

Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00015977

COMPLETED Phase 2

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

NCT00683046

COMPLETED Phase 1

SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT00026377

COMPLETED Phase 2

PS-341 in Treating Patients With Metastatic Kidney Cancer

NCT00025376

COMPLETED Phase 1

Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

NCT00026299

COMPLETED Phase 2

BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer

NCT00022477

COMPLETED

A Multicenter Trial of Academic Hospitalists

NCT00204048

COMPLETED NA

Texture Analysis for Postmenopausal Osteoporosis

NCT00145977

COMPLETED NA

The Effectiveness of Car Seat Checks at Routine Pediatric Visits

NCT00152568

COMPLETED Phase 2

Family Therapy for Adolescent Bulimia Nervosa

NCT00518843

COMPLETED Phase 2

ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck

NCT00015964

COMPLETED NA

Doula Support for Young Mothers: A Randomized Trial

NCT01925664

COMPLETED Phase 2

O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma

NCT00005066

← Previous Page 15 of 16 Next →

Phase Distribution

PhaseTrial count
Phase 1 137
Phase 2 156
Phase 3 14
Phase 4 53

What is open in the University of Chicago pipeline

158 recruiting of 796 indexed (20% open); 451 completed (57%).

Phase mix: 67 late (III/IV) vs 293 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (11 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Chicago: open-pipeline peers nationwide

Peers matched on 796 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 14%16%18%20%22% Total trials Recruiting share University of ChicagoDana-Farber Cancer InstituteUniversity of California, San DiegoUniversity of UtahUniversity of Texas Southwestern Medical CenterAcera SurgicalAlign TechnologyAltruBioAlvernia University
University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 796 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

What to do with this University of Chicago page

796 registered trials is a research-attention snapshot, not an endorsement of University of Chicago or any single study.

  • 158 of University of Chicago's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition University of Chicago studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Chicago pipeline card: 796 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.